Press Releases

Sign up for Email Alerts Press Release RSS

02/14/2020
Multinational Inflammatory Bowel Disease Survey Uncovers Striking Differences in Patients’ and Physicians’ Treatment Goals and Disease Management Expectations
Term:Corporate/Financial News
Language:English
02/13/2020
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma
Term:
Language:English
02/06/2020
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019
Term:Corporate/Financial News
Language:English
02/04/2020
BioMotiv and Bristol-Myers Squibb announce the Launch of Anteros Pharmaceuticals
Term:Corporate/Financial News
Language:English
01/31/2020
Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Term:Corporate/Financial News
Language:English
01/15/2020
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer
Term:Corporate/Financial News
Language:English
01/10/2020
Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)
Term:R&D News
Language:English
01/09/2020
New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
Term:Corporate/Financial News
Language:English
01/07/2020
Bristol-Myers Squibb Completes Divestment of Manufacturing Facility in Anagni, Italy
Term:Corporate/Financial News
Language:English
01/06/2020
Bristol-Myers Squibb to Present at the 38th Annual J.P. Morgan Healthcare Conference
Term:Corporate/Financial News
Language:English

Business Wire NewsHQ^sm